Roche says Phase II trial shows enicepatide cuts HbA1c 2.65% in type 2 diabetes patients at 48 weeks
Bitget2026/09/22 05:01- Roche reported positive topline Phase II results for enicepatide, a once-weekly dual GLP-1/GIP agonist, in type 2 diabetes.
- The trial showed clinically meaningful improvements in blood sugar control, with many patients reaching diabetes targets or normal-range glucose levels.
- Participants also recorded sustained weight loss over the study period, supporting enicepatide’s positioning in cardiometabolic disease.
- Safety broadly matched the incretin class, with mostly mild-to-moderate gastrointestinal effects and low treatment discontinuations.
- Roche is running two Phase III weight-management studies, with Phase III diabetes and cardiovascular outcomes programs planned for 1H 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Vodafone (VOD.US) Swings to Loss in First Half, German Operations Major Drag
Vodafone (VOD.US) released its financial results for the first half of fiscal year 2027.
AI gamble backfires! Data center project writedowns and weak tech stock positions drag down SoftBank (SFTBY.US) to a Q2 loss of $7.1 billion
SoftBank recorded its first net loss in nearly two years due to a $3.7 billion impairment loss arising from a U.S. data center project, coupled with mounting market concerns over the sustainability of artificial intelligence (AI) growth impacting the investment giant’s key holdings.
AI Cloud Sector Faces a Key Moment: CoreWeave (CRWV.US) Set to Announce Earnings, Wells Fargo Remains Bullish
CoreWeave (CRWV.US) will release its third-quarter financial report after the U.S. stock market closes on Tuesday. This is seen as a key test for the strength of the new AI cloud sector.
JPMorgan raises target prices for Target and Walmart
Crypto prices
More
